MEK4 function, genistein treatment, and invasion of human prostate cancer cells

Journal of the National Cancer Institute

Volumn 101, Issue 16, 2009, Pages 1141-1155

  Xu, Li ^a   Ding, Yongzeng ^a   Catalona, William J ^a   Yang, Ximing J ^a   Anderson, Wayne F ^a   Jovanovic, Borko ^a   Wellman, Kenji ^a   Killmer, Jaqueline ^b   Huang, Xiaoke ^a   Scheidt, Karl A ^a   Montgomery, R Bruce ^c   Bergan, Raymond C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CTRC Institute for Drug Development   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCKING PROTEIN; GELATINASE A; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; EXPRESSION VECTOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; MALE; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 69249083967     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp227     Document Type: Article

References (63)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843-848.
3. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2(9):657-672.
4. Ruoslahti E. How cancer spreads. Sci Am. 1996;275(3):72-77.
5. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.
6. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001;11(2):143-152.
7. Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res. 1996;8(2):63-67.
8. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 2005;65(8):3470-3478.
9. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773(8):1358-1375.
10. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene. 2006;25(21):2987-2998.
11. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005;65(23):11083-11093.
12. Xu L, Bergan RC. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Mol Pharmacol. 2006;70(3):869-877.
13. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989;49(7):1857-1860.
14. Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest. 1990;50(suppl 201):3-23.
15. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 1993;342(8881):1209-1210.
16. Lakshman M, Xu L, Ananthanarayanan V, et al. Dietary genistein suppresses metastasis of human prostate cancer in mice. Cancer Res. 2008;68:2024-2032.
17. Derijard B, Raingeaud J, Barrett T, et al. Independent human MAP-kinase signal transduction pathways defi ned by MEK and MKK isoforms. Science. 1995;267(5198):682-685.
18. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol. 1996;16(3):1247-1255.
19. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 1995;269(5222):403-407.
20. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984;44(8):3522-3529.
21. Bright RK, Vocke CD, Emmert-Buck MR, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res. 1997;57(5):995-1002.
22. Liu YQ, Kyle E, Patel S, et al. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis. 2001;4(2):81-91.
23. Craft CS, Romero D, Vary CPH, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene. 2007;26(51):7240-7250.
24. Craft CS, Xu L, Romero D, Vary CP, Bergan RC. Genistein induces phenotypic reversion of endoglin defi ciency in human prostate cancer cells. Mol Pharmacol. 2008;73(1):235-242.
25. Ding Y, Xu L, Chen S, et al. Characterization of a method for profi ling gene expression in cells recovered from intact human prostate tissue using RNA linear amplifi cation. Prostate Cancer Prostatic Dis. 2006;9(4):379-391.
26. Ding Y, Xu L, Jovanovic BD, et al. The methodology used to measure differential gene expression affects the outcome. J Biomol Tech. 2007;18(5):321-330.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
28. Derijard B, Hibi M, Wu IH, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76(6):1025-1037.
29. Eswar N, John B, Mirkovic N, et al. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res. 2003;31(13):3375- 3380.
30. Forster MJ. Molecular modelling in structural biology. Micron. 2002;33(4):365-384.
31. Takimoto CH, Glover K, Huang X, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isofl avones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(11, pt 1):1213-1221.
32. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med. 1997;29(2):95-120.
33. Kimira M, Arai Y, Shimoi K, Watanabe S. Japanese intake of fl avonoids and isofl avonoids from foods. J Epidemiol. 1998;8(3):168-175.
34. Wakai K, Egami I, Kato K, et al. Dietary intake and sources of isofl avones among Japanese. Nutr Cancer. 1999;33(2):139-145.
35. Arai Y, Uehara M, Sato Y, et al. Comparison of isofl avones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol. 2000;10(2):127-135.
36. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21(2):113-131.
37. Lotan TL, Lyon M, Huo D, et al. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol. 2007;212(4):386-394.
38. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004;11(12):1192-1197.
39. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007;26(22):3172-3184.
40. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of cyclooxygenase-2 by the activated MEKK1 - > SEK1/MKK4 - > p38 mitogen-activated protein kinase pathway. J Biol Chem. 1998;273(21):12901-12908.
41. Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene. 2004;23(35):5978-5985.
42. Cunningham SC, Gallmeier E, Hucl T, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 2006;66(11):5560-5564.
43. Stearns ME, Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 1993;53(4):878-883.
44. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis. 1997;15(3):246-258.
45. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Signifi cance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003;63(23):8511-8515.
46. Hayes SA, Huang X, Kambhampati S, Platanias LC. Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene. 2003;22(31):4841-4850.
47. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene. 2002;21(54):8272-8281.
48. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun. 1991;179(1):661-667.
49. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specifi c decrease in focal adhesion kinase activity. Mol Pharmacol. 1997;51(2):193-200.
50. Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isofl avones. J Nutr Biochem. 2007;18(6):408-417.
51. Lopez-Lazaro M, Willmore E, Austin CA. Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod. 2007;70(5):763-767.
52. Matsumura A, Ghosh A, Pope GS, Darbre PD. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol. 2005;94(5):431-443.
53. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purifi ed soy isofl avones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer. 2004;48(2):160-170.
54. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/ stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999;59(21):5483-5487.
55. Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 2005;65(23):10984-10991.
56. Schafferhans A, Klebe G. Docking ligands onto binding site representations derived from proteins built by homology modelling. J Mol Biol. 2001;307(1):407-427.
57. Affara NI, Andreu P, Coussens LM. Delineating protease functions during cancer development. Methods Mol Biol. 2009;539:1-32.
58. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev. 2001;20(3-4):321-331.
59. Frame MC, Inman GJ. NCAM is at the heart of reciprocal regulation of E-cadherin- and integrin-mediated adhesions via signaling modulation. Dev Cell. 2008;15(4):494-496.
60. Blouse GE, Botkjaer KA, Deryugina E, et al. A novel mode of intervention with serine protease activity: targeting zymogen activation. J Biol Chem. 2009;284(7):4647-4657.
61. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2):111-137.
62. Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genisteinstimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. Clin Exp Metastasis. 1996;14(4):389-398.
63. Spencer VA, Xu R, Bissell MJ. Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress. Adv Cancer Res. 2007;97:275-294.